Optimer Pharmaceuticals Earnings: Everything You Must Know Now

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Optimer Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.65 in the quarter versus EPS of $-0.23 in the year-earlier quarter.

Revenue: Rose 35.12% to $19.43 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Optimer Pharmaceuticals, Inc. reported adjusted EPS loss of $0.65 per share. By that measure, the company missed the mean analyst estimate of $-0.42. It missed the average revenue estimate of $21.09 million.

Quoting Management: “Net product sales in the first quarter of $16.8 million were essentially flat from the fourth quarter. We believe net product sales, which are derived from shipments to wholesalers and specialty pharmacies, were negatively impacted by an inventory sell-down by wholesalers. We saw a nearly 5% increase in demand for DIFICID during the quarter, as determined by estimated shipments from wholesalers to hospitals and retail and long-term care pharmacies, and we see continuing increased demand through April,” said Dr. Henry McKinnell, Optimer’s CEO and Chairman of the Board. “As we move toward mid-year and beyond, I am confident that if we maintain our focus on establishing DIFICID as an important treatment option for patients with CDAD, including execution on the strategic initiatives started in the latter part of 2012, we will improve adoption of DIFICID.”

Key Stats (on next page)…